Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) SVP Adam Veness sold 30,000 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total value of $2,424,000.00. Following the completion of the sale, the senior vice president owned 30,000 shares of the company’s stock, valued at $2,424,000. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Dianthus Therapeutics Stock Up 0.7%
Shares of DNTH traded up $0.60 during midday trading on Thursday, reaching $82.49. 2,478,036 shares of the stock were exchanged, compared to its average volume of 927,592. Dianthus Therapeutics, Inc. has a twelve month low of $16.64 and a twelve month high of $96.50. The company has a market cap of $4.51 billion, a P/E ratio of -19.97 and a beta of 1.18. The stock’s 50 day simple moving average is $86.81 and its 200 day simple moving average is $66.00.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The business had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. As a group, analysts predict that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.
Institutional Trading of Dianthus Therapeutics
Analyst Ratings Changes
Several brokerages have recently commented on DNTH. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Truist Financial boosted their price target on Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, March 9th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $117.82.
Check Out Our Latest Research Report on DNTH
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
See Also
- Five stocks we like better than Dianthus Therapeutics
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
